Tweet
CLC bio partners and integrates with Ingenuity
CLC bio and Ingenuity Systems Integrate Pathway and Genomics Analysis Solutions.
Ingenuity Systems and CLC bio announced that they're collaborating to provide interoperability between their software solutions. The aim of the partnership is to provide researchers with the ability to easily exchange data between CLC bio's enterprise and desktop solutions and Ingenuity’s pathway analysis software (IPA®), in order to perform both array and next-generation sequencing data and knowledge analyses.
"As our customers begin to utilize additional research platforms such as next-generation sequencing studies, we see a growing need for solutions that can address the data bottleneck and provide relevant biological context to the data being analyzed," stated Doug Bassett, Ph.D, Ingenuity’s Chief Scientific Officer and Chief Technology Officer, and continues “IPA provides high quality, structured biomedical content and analytics, both of which are critical to realize the full potential of high-throughput sequencing data and get to insight quickly. We are enthusiastic to be part of an integrated solution with CLC bio that will enable researchers to get maximum value from both array and NGS data."
"The costs of sequencing full genomes are now at a price level where we see a lot of industries and research areas moving into high-throughput sequencing in order to benefit from the added scientific value these new technologies can provide." says Director of Consulting Solutions at CLC bio, Jannick D. Bendtsen, PhD, and adds, "The interoperability of Ingenuity’s IPA with CLC Genomics Server and CLC Genomics Workbench is a solution that will provide an efficient workflow experience for scientists working with large next-generation sequencing datasets, directly from high-performance analyses to biomarker discovery and research diagnostic development."
The first milestone of the partnership is focused upon streamlined workflows between CLC bio's award-winning CLC Genomics Server, CLC Genomics Workbench, and Ingenuity’s IPA.
About Ingenuity
About CLC bio
Ingenuity Systems and CLC bio announced that they're collaborating to provide interoperability between their software solutions. The aim of the partnership is to provide researchers with the ability to easily exchange data between CLC bio's enterprise and desktop solutions and Ingenuity’s pathway analysis software (IPA®), in order to perform both array and next-generation sequencing data and knowledge analyses.
"As our customers begin to utilize additional research platforms such as next-generation sequencing studies, we see a growing need for solutions that can address the data bottleneck and provide relevant biological context to the data being analyzed," stated Doug Bassett, Ph.D, Ingenuity’s Chief Scientific Officer and Chief Technology Officer, and continues “IPA provides high quality, structured biomedical content and analytics, both of which are critical to realize the full potential of high-throughput sequencing data and get to insight quickly. We are enthusiastic to be part of an integrated solution with CLC bio that will enable researchers to get maximum value from both array and NGS data."
"The costs of sequencing full genomes are now at a price level where we see a lot of industries and research areas moving into high-throughput sequencing in order to benefit from the added scientific value these new technologies can provide." says Director of Consulting Solutions at CLC bio, Jannick D. Bendtsen, PhD, and adds, "The interoperability of Ingenuity’s IPA with CLC Genomics Server and CLC Genomics Workbench is a solution that will provide an efficient workflow experience for scientists working with large next-generation sequencing datasets, directly from high-performance analyses to biomarker discovery and research diagnostic development."
The first milestone of the partnership is focused upon streamlined workflows between CLC bio's award-winning CLC Genomics Server, CLC Genomics Workbench, and Ingenuity’s IPA.
About Ingenuity
About CLC bio
